Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative study

Leukemia Research

Volumn 15, Issue 2-3, 1991, Pages 81-90

[No Author Info available]

Author keywords

ATL; HTLV I; multivariate analysis; prognostic factor; risk group

Indexed keywords

ADULT; ARTICLE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA; T CELL LYMPHOMA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CALCIUM; FEMALE; FOLLOW-UP STUDIES; HUMAN; LACTATE DEHYDROGENASE; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; MALE; MIDDLE AGE; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE;

EID: 0025872817     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(91)90087-A     Document Type: Article

References (44)

1. Adult T cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera
2. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease
3. Adult T-cell leukemia: Clinical and hematologic features of 16 cases
4. A proposal for smoldering adult T-cell leukemia (smoldering ATL): A clinicopathologic study of 5 cases
5. Atypical adult T-cell leukemia-lymphoma: Diverse clinical manifestations of adult T-cell leukemia leukemia-lymphoma
6. Preleukemic state of adult T cell leukemia: Abnormal T lymphocytosis induced by human adult T cell leukemia-lymphoma virus
7. Variation in the clinical courses of adult T-cell leukemia
8. Adult T-cell leukemia-lymphoma and its clinical subtypes from the viewpoints of viral etiology
9. The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy
10. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia
11. The third nationwide study on adult T-cell leukemia/lymphoma (ATL) in Japan Characteristic patterns of HLA antigen and HTLV-I infection in ATL patients and their relatives
12. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features
13. Combination chemotherapy of advanced lymphocytic lymphoma
14. Chemotherapy of malignant blymphoma
15. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M
16. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma
17. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma
18. A new agglutination test for serum antibodies to adult T-cell leukemia virus
19. Enzyme-linked immunosorbent assay of antibodies to adult T-cell leukemia-associated antigens
20. Prevalence of antibodies to human T-cell leukemia/lymphoma virus type I and human immunodeficiency virus in Japanese immigrant colonies in Bolivia and Bolivian natives
21. Report of the committee on Hodgkin's disease staging classification
22. Some problems on the histopathological diagnosis of non-Hodgkin's malignant lymphoma—a proposal of a new type
23. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma
24. Interpretation of serum calcium in patients with abnormal serum proteins
25. Nonparametric estimation from incomplete observations
26. Evaluation of survival data and two new rank order statistics arising in its consideration
27. Regression models and life tables
28. The PHGLM procedure
29. T-cell phenotype is associated with decreased survival in non-Hodgkin's lymphoma
30. Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M)
31. Treatment of diffuse poorly differentiated lymphocyte lymphoma
32. Stage IV diffuse large-cell lymphoma: A long-term analysis
33. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma
34. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The southwest oncology group experience
35. Combined modality therapy of advanced non-Hodgkin's lymphoma: An analysis of remission duration and survival in 95 patients
36. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)
37. A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma
38. Phase III study of BCOP v. CHOP in unfavorable categories of malignant lymphoma: A southeastern cancer study group trial
39. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma
40. Predictive model for prognosis in advanced diffuse histiocytic lymphoma
41. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD
42. Intensive chemotherapy in aggressive lymphomas: Updated results of LNH-80 protocol and prognostic factors affecting response and survival
43. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma